Peptide Blend COA: How to Verify Each Component, Not Just the Purity %

A single HPLC purity percentage on a three- or four-component blend is close to meaningless as a composition check. Purity, as normally calculated, is main-peak area divided by total peak area: it measures how little non-peptide material is present, not how the peptide mass is split between the components you paid for. A vial can honestly report 99% purity while carrying the wrong ratio, or while one component is present only in trace amounts, because every peak in the chromatogram is still a legitimate peptide peak. What separates a real blend certificate from a repurposed single-peptide template is per-component work: a mass-spectrometry identity result matched to each component’s theoretical mass, and a quantified content figure per component measured against a reference standard. If a blend COA does not give you both, it has not answered the only question a blend raises - what is actually in the vial, and in what proportion.

Published 2026 - For research use only (RUO). Nothing here is medical advice, a dosing protocol, or a human-use recommendation.

In a hurry? Jump to how Pepora scores on the checklist →

---

Why one purity number cannot describe a blend

Start with how the number is produced. HPLC purity is an area normalisation: the target peak’s area divided by the summed area of all peaks, expressed as a percentage. That calculation is designed for a single substance, where everything that is not the main peak is by definition an impurity. Apply it to a deliberate mixture and the logic collapses - there is no single “main peak,” and the other components are not impurities.

The deeper problem is that peak area is not proportional to mass across different peptides. At 214 nm, the wavelength used for most peptide work, the signal comes overwhelmingly from the peptide bond, which Kuipers and Gruppen measured at a molar extinction coefficient of 923 M⁻¹cm⁻¹ [3]. A peptide’s absorbance from that term therefore scales with how many peptide bonds it carries - one fewer than its residue count - not with how many milligrams of it are in the vial. Side chains compound the effect. In the same work, tryptophan absorbs roughly thirty times a peptide bond at this wavelength; phenylalanine, tyrosine and histidine roughly six times; and proline, which has a negligible coefficient as a free amino acid, absorbs about three times a peptide bond once it sits inside a chain [3].

Work this through on a common GLOW-style split - GHK-Cu 50 mg, TB-500 10 mg, BPC-157 10 mg in a 70 mg vial. The molecular weights are from PubChem [10]:

Component	Vial mass	MW (g/mol)	Residues	Peptide bonds	µmol in vial	Mass share	Rough UV₂₁₄ area share
GHK-Cu	50 mg	~403.9	3	2	~123.8	71.4%	~57%
TB-500 (Tβ4)	10 mg	~4963.5	43	42	~2.0	14.3%	~20%
BPC-157	10 mg	~1419.5	15	14	~7.0	14.3%	~23%

The area column is a first-order estimate using the peptide-bond term alone: micromoles multiplied by peptide-bond count, then normalised across the three. You can reproduce it in a spreadsheet in a minute, which is the point of showing it. Even at that crude level, a vial that is 71% GHK-Cu by mass shows up as roughly 57% of the chromatogram area, and BPC-157 at 14% by mass reads as roughly 23%. Adding the side-chain terms moves it further and in compound-specific directions - GHK-Cu’s single histidine pushes its share up, and BPC-157’s four prolines (sequence GEPPPGKPADDAGLV) push its share up too. That is the point: the correction factor is different for every component, and you cannot compute it from the certificate.

Converting area to mass reliably needs a reference standard, or a spiked internal standard, for each component individually. Reference-free approaches have been published - Moffatt and colleagues estimated extinction coefficients from the amino acid sequence and quantified against an internal standard - but that work also documents where the accuracy goes: agreement with expected values was closer for tryptophan-containing peptides than for those carrying only tyrosine [4]. It is a sequence-based estimate whose error depends on composition, not a standard-referenced assay.

So a blend COA that reports one purity figure has told you the vial contains mostly peptide. It has not told you which peptides, or in what proportion.

Purity, content and identity are three different measurements

USP General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances (official 1 August 2021), treats these as separate attributes: general characteristics and specification, peptide content and assay, and impurities and related compounds are listed distinctly, alongside water content, counter-ion content and elemental impurities [8]. Grey-market blend COAs routinely collapse all of it into one percentage.

Question	What answers it	What does not answer it
Identity - is this the right molecule?	Mass spectrometry: observed mass vs theoretical, per component	Retention time alone; a product name
Purity - how much junk is present?	HPLC area normalisation, with all peaks assigned	A number with no chromatogram
Content / ratio - how many mg of each?	Assay against a reference standard per component; amino acid analysis or elemental analysis for net peptide content [11]	HPLC area %

The gap between purity and content is not academic. A candidate certified reference material of angiotensin II - a peptide of high chromatographic purity - was assigned a purity of 691 ± 9 mg/g (k = 2) by combining quantitative NMR, LC-MS/MS amino acid analysis and a mass-balance approach that measured the TFA counter-ion by ¹⁹F NMR [5]. That is roughly 69% peptide by mass, the balance being water and counter-ion, on material specifically prepared to serve as a reference standard.

And the methods that measure content disagree with each other. A comparison of four assays for peptide content in lyophilised thymalfasin - elemental (CHN) analysis, quantitative amino acid analysis, HPLC and Kjeldahl - found that the amino acid analysis and HPLC results varied by laboratory, with AAA “highly variable in one laboratory while quite precise in another,” while CHN analysis returned under 2% coefficient of variation and was the method the author recommended [6]. That is how much slack sits inside a number most blend certificates do not report at all.

---

What a real blend COA must show

Here is the checklist. Anything a certificate cannot supply is a gap you carry, not a gap you can argue away.

#	Requirement	Why it exists	Fail signal
1	Every component named, with sequence or CAS, not just the blend’s trade name	Identity is per-molecule; “GLOW” is not a chemical specification	Certificate header reads only the product name
2	A mass-spec result per component - observed mass matched to that component’s theoretical mass, with the convention stated (monoisotopic vs average)	Retention time is not identity; it is circumstantial	One MS trace, or one m/z value, for a multi-peptide vial
3	A quantified content figure per component, in mg or mg/vial, against a reference standard	This, and only this, establishes the ratio	A single “HPLC purity ≥99%” line standing in for composition
4	The chromatogram plus the integrated peak table, with each peak assigned to a component or flagged as unknown	Lets you see a missing component, an unassigned peak, or a suspiciously small area	Summary page only, no trace
5	Full method conditions: column, gradient, run time, flow, detection wavelength, injection volume	Tells you whether the method could resolve and retain all components at once	No method section, or a method copied from a single-peptide SOP
6	Water content and counter-ion content (Karl Fischer; acetate/TFA)	Gross vial mass is not net peptide mass, and the load is not necessarily even across components	No content data of any kind
7	A lot number matching the vial, and a lab-side lookup by accession or verification key	A PDF is trivially edited; the lab’s own database is not	A screenshot you cannot re-pull at the source

Items 2 and 3 are the ones that distinguish a blend COA from a single-peptide COA with a different title. Everything else on the list applies to any peptide certificate, and is covered in more depth in how to read a peptide COA and how to verify a COA at the lab’s source.

The four shortcuts, and how each one shows itself

Shortcut 1: the aggregate purity line. One number, no per-component breakdown. Spot it by asking a simple question of the certificate: if I removed one component entirely, would this number change much? If the answer is no, the number is not a composition check.

Shortcut 2: pre-blend certificates stapled together. The vendor tests each raw peptide before mixing and supplies those separate certificates. This is genuinely better than nothing - it shows the input materials were characterised - but it says nothing about the fill. Weighing error, incomplete transfer, and a mis-set filling head all occur after the point those certificates describe. Spot it by checking whether the lot numbers on the component certificates tie to the lot number on the vial, or whether they are unrelated lot codes with earlier dates.

Shortcut 3: the small polar component that never made it into the integration window. GHK-Cu (~403.9 g/mol) and KPV (~342.4 g/mol) are tripeptides with very little C18 retention. Under a gradient tuned to resolve BPC-157 and a 43-residue thymosin, they elute early - near the void volume, where salts, TFA and injection artefacts also elute. If the integration window starts after the void, or the baseline in that region is messy, the small component can be excluded from the calculation entirely. Spot it by reading the method’s gradient start against the reported retention times: a component with a retention time at or barely above the column’s dead time has not been chromatographically demonstrated. It has been assumed.

Shortcut 4: co-elution treated as resolution. Two components, or a component and a related impurity, arriving at the same retention time merge into one peak, and the area gets attributed to whichever the analyst expected. Reversed-phase alone cannot rule this out. The published answer is orthogonality - running a second separation on a different mechanism. A 2025 study analysing four synthetic cyclic peptides confirmed that HILIC is genuinely orthogonal to RP-HPLC for peptide impurities and gave more accurate purity determination; the authors’ explicit recommendation was to run the two modes in parallel, not to replace RP-HPLC with HILIC [9]. Almost no grey-market blend certificate includes an orthogonal method. That is not automatically a red flag, but it does mean a single RP run is the ceiling of what the vendor has demonstrated.

---

Blend names are marketing labels, not formulas

There is no monograph, no pharmacopeial standard, and no industry body defining what “GLOW,” “KLOW” or “Wolverine” must contain. These are vendor-coined product names that stabilised through repetition on forums and storefronts. The component lists are broadly consistent - GLOW is GHK-Cu + TB-500 + BPC-157, KLOW adds KPV, Wolverine is BPC-157 + TB-500 - but the masses and ratios are set by whoever filled the vial.

The practical consequence: two vials labelled identically can differ in total mass, in the split between components, and in which component dominates. A 70 mg GLOW at 50/10/10 and a 60 mg GLOW at 30/20/10 are both legitimately “GLOW.” Any comparison you make between vendors on price, and any calculation you run in a cost-per-mg calculator or reconstitution calculator, is only valid once you have the per-component masses from the label and the certificate - not from the name.

This also means a vendor cannot be caught out by a spec that does not exist. There is no external standard to fail. The only enforcement mechanism available to a buyer is the batch certificate, which is precisely why the shortcuts above matter more here than in any single-peptide category.

For the component-level detail on each formulation, see the GLOW blend guide, the KLOW blend guide and the Wolverine blend guide.

---

What this means for vetting a vendor

The grey market’s baseline is worse than most buyers assume, and the evidence for that is published rather than anecdotal.

• In a JAMA analysis of 44 products marketed as selective androgen receptor modulators and sold online, only 23 (52%) contained one or more of the SARMs claimed, another 17 (39%) contained a different unapproved drug, 4 (9%) contained no active compound at all, and the amount of the labelled compound differed substantially from the label in 26 of 44 products (59%) [1]. Different compound class, same supply chain and the same labelling culture.
• A Belgian government screening of ten falsified polypeptide products, sourced from three suspected illegal internet pharmacies, found purity ranging between 5% and 75% for cysteine-containing peptides, and detected the class 1 elemental impurities arsenic and lead - with arsenic at up to ten times the ICH toxicity limit for parenteral drugs in multiple samples [2].
• A 2020 analysis of seized pharmaceutical preparations found the research peptides Selank and Semax present with no indication that they were declared or appropriately labelled [7].

Against that baseline, here are the criteria that are actually checkable before you pay:

1. Does a certificate exist for the blend vial’s own lot number, or only for the pre-blend components? Ask directly. The answer is binary and the vendor knows it.
2. Is the testing lab named, and can you re-pull the report at the lab’s own site by accession or verification key? A PDF the vendor emails you proves nothing on its own.
3. Is there a per-component quantified content figure, or only a purity percentage? If only purity, the ratio is unverified - say that plainly to yourself before buying, rather than after.
4. Does the certificate include the chromatogram and method conditions? Without the trace, you cannot check whether the polar components were retained or the peaks resolved.
5. Is water content or net peptide content reported anywhere? Rarely yes in this market. Its absence means gross vial mass is your only figure, and gross mass overstates peptide mass.
6. Does the vendor claim a third-party COA for products that do not have one? A vendor that publishes real certificates for a defined set of SKUs and stays silent on the rest is behaving more honestly than one that implies blanket coverage.

Criteria 2 and 6 are the ones that generalise beyond blends - they are the backbone of the vendor transparency scorecard, and the failure patterns are catalogued in peptide vendor red flags and how to vet a US peptide vendor.

---

How Pepora scores

Applying the checklist above to Pepora (peporalabs.com) honestly means separating what is verifiable from what is not, because the two do not overlap perfectly with the blend catalogue.

What is verifiable. Pepora publishes third-party certificates from Freedom Diagnostics, a US lab running HPLC with UV detection and mass spectrometry, and those reports are re-checkable by accession number at the lab’s own site rather than existing only as vendor-hosted PDFs. Four SKUs currently carry accession-verifiable Freedom Diagnostics COAs:

SKU	Reported purity	Freedom Diagnostics accession
GHK-Cu	99.98%	Pepo2603130126
Tesamorelin	99.348%	Pepo2603130125
TB-500 / Thymosin Beta-4	99.699%	Pepo2603130123
GLP-3 RT	99.67%	Pepo2603130122

The caveat that matters for this article. Those four are single-peptide SKUs, not blend vials. Two of them are also blend components - GHK-Cu appears in GLOW and KLOW, and TB-500 appears in GLOW, KLOW and Wolverine - so for those two you can pull an independent US lab’s report on the standalone SKU and check its mass-spec figure against the published molecular weights yourself. BPC-157, KPV, Epitalon, Thymosin Alpha-1, ARA-290 and the assembled blend vials are not covered by an accession-verifiable Freedom Diagnostics report, and this site does not claim they are.

Read that as what it is: partial coverage, disclosed. The honest score for a Pepora blend is “two of the three GLOW components are sold as separately tested single-peptide SKUs whose certificates you can resolve at the lab, and the blend fill itself is not certified by a third party.” Note the limit precisely: a COA on the standalone GHK-Cu SKU is not a COA on the material that went into a particular blend lot unless the lot numbers tie. That is still better than a single aggregate purity number from an unnamed in-house bench, and it is short of the per-component content assay on the blend lot that the checklist above describes. If a vendor - any vendor, including this one - cannot show you a certificate for the blend vial’s own lot, the ratio in that vial is taken on trust. Ships from the US.

---

The disclosed pick

---

FAQ

What should a peptide blend COA show that a single-peptide COA does not? Three extra things. First, a per-component identity result - a mass-spectrometry observed mass matched to each component’s theoretical mass, not one MS trace for the vial. Second, a per-component content or assay figure in mg (or mg/vial) measured against a reference standard, which is what tells you the ratio. Third, an integrated chromatogram with every peak assigned, so you can see whether a component is present at all. A blend certificate carrying only one aggregate “HPLC purity 99%” line is a single-peptide template applied to a multi-peptide product.

Can a peptide blend be 99% pure and still have the wrong ratio? Yes, and this is the central problem. HPLC purity is normally calculated as main-peak area divided by total peak area, so it measures how little non-peptide material is present, not how the peptide mass is distributed between components. A vial could contain most of one component and only a trace of the second, and still report a very high combined purity because both peaks are legitimate peptide peaks. Purity and composition are different questions answered by different measurements.

Does HPLC area percent tell you how many mg of each peptide are in a blend? Not reliably. Area percent would only track mass if every component absorbed UV in proportion to its mass, and it does not. At 214 nm the signal comes mainly from the peptide bond, so a 43-residue peptide has 42 peptide bonds against a tripeptide’s two - roughly 21 times the absorbance per molecule from that term alone - and side chains such as tryptophan, tyrosine, phenylalanine, histidine and proline add more on top [3]. Turning area into mass needs a per-component correction: a reference standard for each component, or the published reference-free route of calculating an extinction coefficient from each component’s own sequence and quantifying against an internal standard, whose accuracy varies with amino acid composition [4]. A bare area percentage supplies neither.

How can you tell whether a blend vial is missing a component entirely? Ask for the chromatogram and the integrated peak table, not just the summary page. Each named component should appear as an assigned peak with a retention time, and the method section should show a gradient and run time capable of retaining all of them. Very polar tripeptides such as GHK-Cu and KPV have little retention on a C18 column and elute close to the void volume, where salts and counter-ions also elute, so under a gradient tuned for larger peptides they can be integrated away or fall outside the reported window.

Are GLOW, KLOW and Wolverine standardised formulas? No. They are marketing names, not pharmacopeial formulations. There is no USP monograph or any other public standard defining what mass of each component a vial labelled GLOW or KLOW must contain, so two vials with the same name from different suppliers can differ in both total mass and internal ratio. The vial label and the batch certificate are the only source of truth; the product name carries no specification at all.

What is net peptide content and why does it matter more for a blend? Net peptide content is the share of the vial’s gross weight that is actually peptide, excluding water, counter-ions such as acetate or TFA, and residual solvent. It is measured by amino acid analysis or elemental analysis, not by HPLC, and it can sit well below gross mass - a candidate certified reference material of angiotensin II was assigned 691 ± 9 mg/g, roughly 69% peptide by mass, and that was material prepared to serve as a reference standard [5]. In a blend the counter-ion and water load is not necessarily shared evenly across components, so a vial filled to a stated gross total can be short on net peptide in a way no purity figure reveals.

---

References

1. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA. 2017;318(20):2004-2010. PMID: 29183075. https://pubmed.ncbi.nlm.nih.gov/29183075/
2. Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. PMID: 30029448. https://pubmed.ncbi.nlm.nih.gov/30029448/
3. Kuipers BJH, Gruppen H. Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. J Agric Food Chem. 2007;55(14):5445-5451. PMID: 17539659. https://pubmed.ncbi.nlm.nih.gov/17539659/
4. Moffatt F, Senkans P, Ricketts D. Approaches towards the quantitative analysis of peptides and proteins by reversed-phase high-performance liquid chromatography in the absence of a pure reference sample. J Chromatogr A. 2000;891(2):235-242. PMID: 11043783. https://pubmed.ncbi.nlm.nih.gov/11043783/
5. Melanson JE, Thibeault MP, Stocks BB, Leek DM, McRae G, Meija J. Purity assignment for peptide certified reference materials by combining qNMR and LC-MS/MS amino acid analysis results: application to angiotensin II. Anal Bioanal Chem. 2018;410(26):6719-6731. PMID: 30143839. https://pubmed.ncbi.nlm.nih.gov/30143839/
6. Vemuri S. Comparison of assays for determination of peptide content for lyophilized thymalfasin. J Pept Res. 2005;65(4):433-439. PMID: 15813890. https://pubmed.ncbi.nlm.nih.gov/15813890/
7. Vanhee C, Francotte A, Janvier S, Deconinck E. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: an incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal. 2020;12(3):371-381. PMID: 31667971. https://pubmed.ncbi.nlm.nih.gov/31667971/
8. United States Pharmacopeia. General Chapter <1503> Quality Attributes of Synthetic Peptide Drug Substances. USP-NF; official 1 August 2021. https://doi.usp.org/USPNF/USPNF_M12935_02_01.html
9. Impurity profiling of synthetic cyclic peptides based on orthogonality between hydrophilic-interaction and reversed-phase liquid chromatography. J Chromatogr A. 2025. https://www.sciencedirect.com/science/article/pii/S0021967325000974
10. PubChem compound records used for molecular weights: BPC-157 (CID 9941957, C62H98N16O22, ~1419.5) https://pubchem.ncbi.nlm.nih.gov/compound/9941957 ; timbetasin / thymosin beta-4 (CID 16132341, C212H350N56O78S, ~4963.5) https://pubchem.ncbi.nlm.nih.gov/compound/16132341 ; Cu-GHK / copper tripeptide-1 (CID 378611, C14H24CuN6O4, ~403.9) https://pubchem.ncbi.nlm.nih.gov/compound/378611 ; MSH(11-13) / KPV (CID 125672, C16H30N4O4, ~342.4) https://pubchem.ncbi.nlm.nih.gov/compound/125672
11. Rutherfurd SM, Gilani GS. Amino acid analysis. Curr Protoc Protein Sci. 2009 Nov. PMID: 19937719. https://pubmed.ncbi.nlm.nih.gov/19937719/

---

coaindex is a Pepora affiliate (peporalabs.com) and earns a commission on purchases made with the code above. This is affiliate education, not journalism, and it ranks vendors on checkable, independently verifiable third-party-COA criteria. Research use only. Not for human or veterinary use, and nothing here is medical advice.